Sonic hedgehog signalling as a potential endobronchial biomarker in COPD.


Journal

Respiratory research
ISSN: 1465-993X
Titre abrégé: Respir Res
Pays: England
ID NLM: 101090633

Informations de publication

Date de publication:
07 Aug 2020
Historique:
received: 21 01 2020
accepted: 02 08 2020
entrez: 10 8 2020
pubmed: 10 8 2020
medline: 3 7 2021
Statut: epublish

Résumé

The hedgehog (HH) pathway has been associated with chronic obstructive pulmonary disease (COPD) in genome-wide association studies and recent studies suggest that HH signalling could be altered in COPD. We therefore used minimally invasive endobronchial procedures to assess activation of the HH pathway including the main transcription factor, Gli2, and the ligand, Sonic HH (Shh). Thirty non-COPD patients and 28 COPD patients were included. Bronchial brushings, bronchoalveolar lavage fluid (BALF) and bronchial biopsies were obtained from fiberoptic bronchoscopy. Characterization of cell populations and subcellular localization were evaluated by immunostaining. ELISA and RNAseq analysis were performed to identify Shh proteins in BAL and transcripts on lung tissues from non-COPD and COPD patients with validation in an external and independent cohort. Compared to non-COPD patients, COPD patients exhibited a larger proportion of basal cells in bronchial brushings (26 ± 11% vs 13 ± 6%; p < 0.0001). Airway basal cells of COPD subjects presented less intense nuclear staining for Gli2 in bronchial brushings and biopsies (p < 0.05). Bronchial BALF from COPD patients contained lower Shh concentrations than non-COPD BALF (12.5 vs 40.9 pg/mL; p = 0.002); SHH transcripts were also reduced in COPD lungs in the validation cohort (p = 0.0001). This study demonstrates the feasibility of assessing HH pathway activation in respiratory samples collected by bronchoscopy and identifies impaired bronchial epithelial HH signalling in COPD.

Sections du résumé

BACKGROUND BACKGROUND
The hedgehog (HH) pathway has been associated with chronic obstructive pulmonary disease (COPD) in genome-wide association studies and recent studies suggest that HH signalling could be altered in COPD. We therefore used minimally invasive endobronchial procedures to assess activation of the HH pathway including the main transcription factor, Gli2, and the ligand, Sonic HH (Shh).
METHODS METHODS
Thirty non-COPD patients and 28 COPD patients were included. Bronchial brushings, bronchoalveolar lavage fluid (BALF) and bronchial biopsies were obtained from fiberoptic bronchoscopy. Characterization of cell populations and subcellular localization were evaluated by immunostaining. ELISA and RNAseq analysis were performed to identify Shh proteins in BAL and transcripts on lung tissues from non-COPD and COPD patients with validation in an external and independent cohort.
RESULTS RESULTS
Compared to non-COPD patients, COPD patients exhibited a larger proportion of basal cells in bronchial brushings (26 ± 11% vs 13 ± 6%; p < 0.0001). Airway basal cells of COPD subjects presented less intense nuclear staining for Gli2 in bronchial brushings and biopsies (p < 0.05). Bronchial BALF from COPD patients contained lower Shh concentrations than non-COPD BALF (12.5 vs 40.9 pg/mL; p = 0.002); SHH transcripts were also reduced in COPD lungs in the validation cohort (p = 0.0001).
CONCLUSION CONCLUSIONS
This study demonstrates the feasibility of assessing HH pathway activation in respiratory samples collected by bronchoscopy and identifies impaired bronchial epithelial HH signalling in COPD.

Identifiants

pubmed: 32767976
doi: 10.1186/s12931-020-01478-x
pii: 10.1186/s12931-020-01478-x
pmc: PMC7412648
doi:

Substances chimiques

Biomarkers 0
Hedgehog Proteins 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

207

Références

N Engl J Med. 2010 Sep 16;363(12):1128-38
pubmed: 20843247
COPD. 2017 Jun;14(3):367-374
pubmed: 28388265
Thorax. 2013 Aug;68 Suppl 1:i1-i44
pubmed: 23860341
J Dev Biol. 2019 Jul 09;7(3):
pubmed: 31323955
Proc Natl Acad Sci U S A. 2016 Aug 9;113(32):E4681-7
pubmed: 27444019
Am J Respir Cell Mol Biol. 2019 Jul;61(1):31-41
pubmed: 30995076
J Cell Biochem. 2014 Sep;115(9):1469-77
pubmed: 24644090
Int J Chron Obstruct Pulmon Dis. 2019 Oct 03;14:2267-2272
pubmed: 31631996
Lancet Respir Med. 2015 Oct;3(10):782-95
pubmed: 26404118
Immunol Allergy Clin North Am. 2005 Aug;25(3):469-88
pubmed: 16054538
Am J Respir Crit Care Med. 2017 Mar 15;195(6):757-771
pubmed: 27669027
Clin Sci (Lond). 2017 Jul 16;131(15):2019-2035
pubmed: 28522681
Am J Respir Cell Mol Biol. 2017 Jul;57(1):47-58
pubmed: 28248572
Respir Res. 2019 Jul 12;20(1):152
pubmed: 31299954
Am J Pathol. 2012 Dec;181(6):2126-37
pubmed: 23031257
Nat Med. 2019 Jul;25(7):1153-1163
pubmed: 31209336
J Allergy Clin Immunol. 2011 Jun;127(6):1457-65
pubmed: 21397937
Sci Rep. 2019 Mar 4;9(1):3353
pubmed: 30833624
Chin Med J (Engl). 2018 May 20;131(10):1191-1198
pubmed: 29722338
Development. 2019 Oct 23;146(20):
pubmed: 31558434
Am J Physiol Lung Cell Mol Physiol. 2012 Dec 1;303(11):L978-90
pubmed: 23023967
Dis Model Mech. 2010 Sep-Oct;3(9-10):545-56
pubmed: 20699479
Oncotarget. 2018 Feb 6;9(18):14680-14691
pubmed: 29581874
Am J Respir Cell Mol Biol. 2015 Jan;52(1):1-13
pubmed: 25068457
Am J Respir Cell Mol Biol. 2015 Apr;52(4):418-28
pubmed: 25140582
Pac Symp Biocomput. 2016;22:266-275
pubmed: 27896981
Chem Biol. 2012 Aug 24;19(8):972-82
pubmed: 22921064
Cell Commun Signal. 2018 Mar 20;16(1):11
pubmed: 29558958
Mol Med Rep. 2018 Jun;17(6):8557-8563
pubmed: 29658573
Biochem Soc Trans. 2020 Feb 28;48(1):327-336
pubmed: 31922198
Am J Respir Crit Care Med. 2018 Apr 1;197(7):885-896
pubmed: 29211494
Nat Genet. 2017 Mar;49(3):416-425
pubmed: 28166213
Am J Respir Crit Care Med. 2017 Mar 1;195(5):557-582
pubmed: 28128970
J Chin Med Assoc. 2019 May;82(5):343-350
pubmed: 31058710
EBioMedicine. 2020 Jan;51:102572
pubmed: 31877414
Clin Chest Med. 2014 Mar;35(1):7-16
pubmed: 24507833
Respirology. 2016 Nov;21(8):1347-1356
pubmed: 27381663
Am J Respir Cell Mol Biol. 2014 Jul;51(1):11-25
pubmed: 24450438
Chest. 1992 Aug;102(2):356-61
pubmed: 1643913
Lab Invest. 2020 Mar;100(3):363-377
pubmed: 31541181
Mucosal Immunol. 2018 Sep;11(5):1306-1315
pubmed: 29867080
Am J Respir Crit Care Med. 2019 Jun 15;199(12):1517-1536
pubmed: 30554520
Exp Cell Res. 2017 Jun 15;355(2):83-94
pubmed: 28363830

Auteurs

Julien Ancel (J)

University of Reims Champagne-Ardenne, Inserm, P3Cell UMR-S 1250, SFR CAP-SANTE, 45 rue Cognacq-Jay, 51092, Reims, France.
Department of Pulmonary Medicine, University Hospital of Reims, Hôpital Maison Blanche, 51092, Reims, France.

Randa Belgacemi (R)

University of Reims Champagne-Ardenne, Inserm, P3Cell UMR-S 1250, SFR CAP-SANTE, 45 rue Cognacq-Jay, 51092, Reims, France.

Jeanne-Marie Perotin (JM)

University of Reims Champagne-Ardenne, Inserm, P3Cell UMR-S 1250, SFR CAP-SANTE, 45 rue Cognacq-Jay, 51092, Reims, France.
Department of Pulmonary Medicine, University Hospital of Reims, Hôpital Maison Blanche, 51092, Reims, France.

Zania Diabasana (Z)

University of Reims Champagne-Ardenne, Inserm, P3Cell UMR-S 1250, SFR CAP-SANTE, 45 rue Cognacq-Jay, 51092, Reims, France.

Sandra Dury (S)

Department of Pulmonary Medicine, University Hospital of Reims, Hôpital Maison Blanche, 51092, Reims, France.

Maxime Dewolf (M)

Department of Pulmonary Medicine, University Hospital of Reims, Hôpital Maison Blanche, 51092, Reims, France.

Arnaud Bonnomet (A)

University of Reims Champagne-Ardenne, Inserm, P3Cell UMR-S 1250, SFR CAP-SANTE, 45 rue Cognacq-Jay, 51092, Reims, France.
Platform of Cellular and Tissular Imaging (PICT), 51097, Reims, France.

Nathalie Lalun (N)

University of Reims Champagne-Ardenne, Inserm, P3Cell UMR-S 1250, SFR CAP-SANTE, 45 rue Cognacq-Jay, 51092, Reims, France.

Philippe Birembaut (P)

University of Reims Champagne-Ardenne, Inserm, P3Cell UMR-S 1250, SFR CAP-SANTE, 45 rue Cognacq-Jay, 51092, Reims, France.
University Hospital of Reims, Hôpital Maison Blanche, Laboratoire de Biopathologie, 51092, Reims, France.

Myriam Polette (M)

University of Reims Champagne-Ardenne, Inserm, P3Cell UMR-S 1250, SFR CAP-SANTE, 45 rue Cognacq-Jay, 51092, Reims, France.
University Hospital of Reims, Hôpital Maison Blanche, Laboratoire de Biopathologie, 51092, Reims, France.

Gaëtan Deslée (G)

University of Reims Champagne-Ardenne, Inserm, P3Cell UMR-S 1250, SFR CAP-SANTE, 45 rue Cognacq-Jay, 51092, Reims, France.
Department of Pulmonary Medicine, University Hospital of Reims, Hôpital Maison Blanche, 51092, Reims, France.

Valérian Dormoy (V)

University of Reims Champagne-Ardenne, Inserm, P3Cell UMR-S 1250, SFR CAP-SANTE, 45 rue Cognacq-Jay, 51092, Reims, France. valerian.dormoy@univ-reims.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH